ARQT
HealthcareArcutis Biotherapeutics, Inc. · Biotechnology · $3B
What is Arcutis Biotherapeutics, Inc.?
Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for skin diseases, headquartered in Westlake Village, California.
Arcutis builds a pipeline of topical therapies targeting common dermatological conditions. Revenue potential centers on commercializing roflumilast-based treatments for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, alongside earlier-stage candidates targeting hand eczema, vitiligo, and alopecia areata.
Incorporated in 2016 and headquartered in Westlake Village, California, the company adopted its current name in October 2019.
- Roflumilast cream for plaque psoriasis and atopic dermatitis
- Roflumilast foam for seborrheic dermatitis and scalp psoriasis
- Topical JAK1 inhibitor for hand eczema and vitiligo
- Deeper-penetrating topical formulation targeting alopecia areata
Is ARQT a Good Stock to Buy?
UQS Score rates ARQT as Good overall.
The Growth and Risk pillars both register as Strong — reflecting a pipeline advancing toward commercialization and a risk profile that stands out relative to many early-stage biopharma peers. The Moat pillar sits at Neutral, suggesting some differentiation through its topical formulation focus.
The Quality pillar is rated Weak, which is common for companies still scaling revenue and not yet consistently profitable.
Sign up to see the full pillar breakdown and the complete financial metrics behind ARQT's UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ARQT pay dividends?
No — Arcutis Biotherapeutics, Inc. does not currently pay a dividend.
Arcutis does not currently pay a dividend. As a clinical-stage biopharmaceutical company, available capital is directed toward pipeline development and commercialization efforts rather than shareholder distributions.
When does ARQT report earnings?
Arcutis Biotherapeutics reports earnings on a quarterly cadence, typical for US-listed equities.
Quarterly results tend to reflect pipeline progress, product launch trajectory, and operating expense levels as the company moves toward broader commercialization. Investors typically focus on revenue ramp and cash runway updates.
For the most recent quarter's results, visit Arcutis Biotherapeutics' investor relations page directly.
ARQT Price History
-11.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Arcutis Biotherapeutics, Inc.?
Based on Arcutis Biotherapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Arcutis Biotherapeutics do?
Arcutis Biotherapeutics develops topical therapies for dermatological conditions including plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and alopecia areata. Its pipeline is built around roflumilast-based formulations and a selective JAK1 inhibitor.
Does ARQT pay dividends?
No, ARQT does not pay a dividend. The company reinvests capital into its clinical pipeline and commercialization activities, which is typical for biopharmaceutical companies at this stage of growth.
When does ARQT report earnings?
Arcutis reports on a standard quarterly schedule. For exact dates and the most recent results, check the investor relations section of the company's official website.
Is ARQT a good stock to buy?
UQS Score rates ARQT as Good overall, with particularly Strong ratings in Growth and Risk. The Quality pillar is Weak, reflecting the financial profile of a company still scaling. The full pillar breakdown is available to Pro members on uqs-score.com.
Is ARQT overvalued?
ARQT's Valuation pillar is rated Neutral, suggesting the market is pricing the stock in line with its stage and prospects rather than at a clear premium or discount. See the complete valuation metrics by signing up.
What is ARQT's market cap bracket?
ARQT is classified as a mid-cap stock. This places it in a range that typically reflects a company with established pipeline assets but still meaningful execution risk ahead.
Is ARQT a long-term quality indicator?
The UQS framework evaluates long-term quality across five pillars. ARQT's Strong Growth and Risk scores suggest a foundation worth monitoring, though the Weak Quality pillar indicates the business has not yet reached sustained financial strength.
What sector does ARQT belong to?
Arcutis Biotherapeutics operates in the Healthcare sector, specifically within biopharmaceuticals, with a narrow focus on dermatology — a specialty area with significant unmet patient need and recurring treatment demand.
Unlock Full ARQT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics behind the Quality and Growth scores
- ✓Compare ARQT against dermatology and biopharma peers
- ✓Get the complete risk and valuation breakdown in one place
Pro Analysis
ARQT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 55.0 | 19.9 | 40.0 | 100.0 | 79.3 | 53.8 | +0.1 |
| May 22, 2026 | 54.9 | 19.9 | 40.0 | 100.0 | 79.3 | 53.7 | -0.1 |
| May 21, 2026 | 55.0 | 19.9 | 40.0 | 100.0 | 79.3 | 54.2 | -0.2 |
| May 20, 2026 | 55.2 | 19.9 | 40.0 | 100.0 | 79.3 | 55.3 | +0.1 |
| May 19, 2026 | 55.1 | 19.9 | 40.0 | 100.0 | 79.3 | 54.7 | +0.2 |
| May 16, 2026 | 54.9 | 19.9 | 40.0 | 100.0 | 79.3 | 53.4 | +0.1 |
| May 15, 2026 | 54.8 | 19.9 | 40.0 | 100.0 | 79.3 | 53.2 | 0.0 |
| May 14, 2026 | 54.8 | 19.9 | 40.0 | 100.0 | 79.3 | 53.0 | -0.2 |
| May 13, 2026 | 55.0 | 19.9 | 40.0 | 100.0 | 79.3 | 54.0 | +0.1 |
| May 11, 2026 | 54.9 | 19.9 | 40.0 | 100.0 | 79.3 | 53.5 | +4.0 |
ARQT — Pillar Breakdown
Quality
— 19.9/100 (25%)Arcutis Biotherapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Arcutis Biotherapeutics, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 79.3/100 (15%)Arcutis Biotherapeutics, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 53.8/100 (15%)Arcutis Biotherapeutics, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 40/100 (25%)Arcutis Biotherapeutics, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ARQT.
Score Composition
Financial Data
More Stock Analysis
How is the ARQT UQS Score Calculated?
The UQS (Unified Quality Score) for Arcutis Biotherapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Arcutis Biotherapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Arcutis Biotherapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.